323990 — VaxCell Biotherapeutics Co Share Price
0.000.00%
Last trade - 00:00- KR₩252bn
- KR₩219bn
- KR₩2bn
Growth & Value
| 12m Forecast Rolling | Industry | Market | |
|---|---|---|---|
| PE Ratio (f) | n/a | ||
| PEG Ratio (f) | n/a | ||
| EPS Growth (f) | n/a | ||
| Dividend Yield (f) | n/a | ||
| Valuation (ttm) | Industry | Market | |
|---|---|---|---|
| Price to Book Value | 3.03 | ||
| Price to Tang. Book | 3.24 | ||
| Price to Free Cashflow | n/a | ||
| Price to Sales | 114.71 | ||
| EV to EBITDA | n/a | ||
Shareholder Activity
| Type | Buy / Hold / Sell |
|---|---|
| Institutions | |
| Directors | |
| Community |
Guru Screens
Quality
| Name | Industry | Market | |
|---|---|---|---|
| Return on Capital | -20.31% | ||
| Return on Equity | -13.66% | ||
| Operating Margin | -792.76% | ||
Financial Summary
| Year End 31st Dec | Unit | 2020 | 2021 | 2022 | 2023 | 2024 | 2025E | 2026E | CAGR / Avg |
|---|---|---|---|---|---|---|---|---|---|
| Total Revenue | KR₩m | n/a | n/a | n/a | 13.72 | 1,898.93 | n/a | n/a | n/a |
| Operating Profit | m | ||||||||
| Net Profit | m | ||||||||
| EPS Reported | |||||||||
| Diluted Normalised EPS | |||||||||
| EPS Growth | % | n/a | n/a | n/a | n/a | n/a | n/a | n/a | n/a |
| PE Ratio | x | ||||||||
| PEG | |||||||||
| Profitability | |||||||||
| Operating Margin | % | ||||||||
| ROA | % | ||||||||
| ROCE | % | ||||||||
| ROE | % | ||||||||
| Cashflow | |||||||||
| Op. Cashflow ps | |||||||||
| Capex ps | |||||||||
| Free Cashflow ps | |||||||||
| Dividends | |||||||||
| Dividend ps | |||||||||
| Dividend Growth | % | ||||||||
| Dividend Yield | % | ||||||||
| Dividend Cover | x | ||||||||
| Balance Sheet | |||||||||
| Cash etc | m | ||||||||
| Working Capital | m | ||||||||
| NFA | m | ||||||||
| Net Debt | m | ||||||||
| Book Value | m | ||||||||
| Diluted Weighted Average Shares | m | ||||||||
| Book Value ps | |||||||||
Other Ratios
| Leverage (ttm) | Total | - Intang | + Pension |
|---|---|---|---|
| Gross Gearing | |||
| Net Gearing | |||
| Cash / Assets |
| Liquidity (ttm) | |
|---|---|
| Curr. Ratio | |
| Quick Ratio | |
| Interest Cov. | |
| Efficiency (ttm) | |
|---|---|
| Asset Turnover | |
| Recs Turnover | |
| Stock Turnover | |
Recent History
| Latest interim period vs. prior period | Industry | Market | |
|---|---|---|---|
| Sales Growth | |||
| EPS Growth | |||
| 3yr Compound Annual Growth Rate | Industry | Market | |
|---|---|---|---|
| Sales CAGR | |||
| EPS CAGR | |||
| DPS CAGR | |||
Profile Summary
VaxCell Biotherapeutics Co Ltd is a Korea-based company primarily engaged in the research and development of anticancer immunotherapeutic. The Company operates its business through three segments. The Anticancer Immunotherapy Business segment engages in the research and development of Vax-NK natural killer cell anticancer immunotherapy platform, Vax-DC dendritic cell anticancer immunotherapy platform, Vax-CAR series anticancer immunotherapy platform, and small molecule targeted anticancer drug platform. The Pharmaceutical and Medical Supplies Distribution Business segment engages in the wholesale business of pharmaceuticals and medical supplies and related pharmaceutical distribution business. The Companion Animal Healthcare Business segment engages in the manufacturing and sales of cytokine-based Vaxleukin-15 product, an anticancer immunotherapy for companion dogs.
Directors
- Last Annual
- December 31st, 2024
- Last Interim
- December 31st, 2024
- Incorporated
- February 18th, 2010
- Public Since
- September 22nd, 2020
- No. of Shareholders
- 80,216
- No. of Employees
- 81
- Sector
- Biotechnology & Medical Research
- Industry
- Healthcare
- Exchange
- Korea Exchange - KOSDAQ
- Shares in Issue
- 23,173,892
- Address
- Biomaterials Incubation Center, HWASUN, 58120
- Web
- https://www.vaxcell-bio.com/
- Phone
- +82 613730046
- Auditors
- Donghyun Accounting Corp
Upcoming Events for 323990
Q2 2025 VaxCell Biotherapeutics Co Ltd Earnings Release
Similar to 323990
3Billion
Korea Exchange - KOSDAQ
ABion
Korea Exchange - KOSDAQ
ABL Bio
Korea Exchange - KOSDAQ
Amicogen
Korea Exchange - KOSDAQ
AprilBio Co
Korea Exchange - KOSDAQ
FAQ
What is the VaxCell Biotherapeutics Co share price?
As of Today at 23:55 UTC, shares in VaxCell Biotherapeutics Co are trading at KR₩9,400. This share price information is delayed by 15 minutes.
How has the VaxCell Biotherapeutics Co share price performed this year?
Shares in VaxCell Biotherapeutics Co last closed at KR₩9,400 and the price had moved by -41.87% over the past 365 days. In terms of relative price strength the VaxCell Biotherapeutics Co share price has underperformed the FTSE Developed Asia Pacific Index by -41.21% over the past year.
What are the analyst and broker recommendations for VaxCell Biotherapeutics Co?
There is no consensus recommendation for this security.
Find out moreWhat is the VaxCell Biotherapeutics Co dividend yield?
VaxCell Biotherapeutics Co does not currently pay a dividend.
Does VaxCell Biotherapeutics Co pay a dividend?
VaxCell Biotherapeutics Co does not currently pay a dividend.
When does VaxCell Biotherapeutics Co next pay dividends?
VaxCell Biotherapeutics Co does not currently pay a dividend.
How do I buy VaxCell Biotherapeutics Co shares?
To buy shares in VaxCell Biotherapeutics Co you'll need a share-dealing account with an online or offline stock broker. Once you have opened your account and transferred funds into it, you'll be able to search and select shares to buy and sell. You can use Stockopedia’s share research software to help you find the the kinds of shares that suit your investment strategy and objectives.
What is the market cap of VaxCell Biotherapeutics Co?
As of the previous close price of KR₩9,400, shares in VaxCell Biotherapeutics Co had a market capitalisation of KR₩252bn.
Where are VaxCell Biotherapeutics Co shares listed?
Here are the trading details for VaxCell Biotherapeutics Co:
- Country of listing: Korea, Republic of
- Exchange: KOE
- Ticker Symbol: 323990
What kind of share is VaxCell Biotherapeutics Co?
Based on an overall assessment of its quality, value and momentum VaxCell Biotherapeutics Co is currently classified as a Sucker Stock. The classification is based on a composite score that examines a wide range of fundamental and technical measures. Stock are classified on the the following spectrum: Super Stocks, High Flyers, Contrarians, Turnarounds, Neutral, Value Traps, Momentum Traps, Falling Stars, and Sucker Stocks. For more information, learn about our StockRank Styles.
Is there a VaxCell Biotherapeutics Co share price forecast for 2025?
We could not find analyst target price data for this security.
Find out moreWhat is the trend in the VaxCell Biotherapeutics Co share price?
An important predictor of whether a stock price will go up is its track record of momentum. Price trends tend to persist, so it's worth looking at them when it comes to a share like VaxCell Biotherapeutics Co. Over the past six months, its share price has underperformed the FTSE Developed Asia Pacific Index by -18.96%.
As of the last closing price of KR₩9,400, shares in VaxCell Biotherapeutics Co were trading -22.37% below their 200 day moving average. You can read more about the power of momentum in assessing share price movements on Stockopedia.
What is the VaxCell Biotherapeutics Co PE Ratio?
The VaxCell Biotherapeutics Co PE ratio based on its reported earnings over the past 12 months is null. The shares last closed at KR₩9,400.
The PE ratio (or price-to-earnings ratio) is the one of the most popular valuation measures used by stock market investors. It is calculated by dividing a company's price per share by its earnings per share.
The PE ratio can be seen as being expressed in years, in the sense that it shows the number of years of earnings which would be required to pay back the purchase price, ignoring inflation. So in general terms, the higher the PE, the more expensive the stock is.
Who are the key directors of VaxCell Biotherapeutics Co?
We do not have data on VaxCell Biotherapeutics Co's directors